Narasimhan Vignesh (Orcid ID: 0000-0002-8964-3082)
Guerra Glen (Orcid ID: 0000-0002-2505-1643)
Pham Toan (Orcid ID: 0000-0002-9133-4545)

Full Title: Wither Surgical Oncology?

Short Title: Wither Surgical Oncology?

Toan Duc Pham, MBBS, BMedSc, PGDipSurgAnat, FRACS; Peter MacCallum Cancer Centre

Vignesh Narasimhan, MBChB, FRACS; Peter MacCallum Cancer Centre

Glen Guerra, MBBS, PGDipSurgAnat, FRACS; Peter MacCallum Cancer Centre

Joseph Kong, MBChB, MS, PhD, FRACS; Peter MacCallum Cancer Centre

Jayesh Desai, MBBS, FRACP; Peter MacCallum Cancer Centre

Robert Ramsay, BSc (Hons), PhD; Peter MacCallum Cancer Centre

Alexander Heriot, MBBChir, MA, MD, FRCS (Gen.), FRCS(Ed), FRACS; Peter MacCallum
Cancer Centre

Corresponding Author:

Toan Duc Pham – Recipient of the RACS Tour de Cure Scholarship 2018

Email: toan.pham@petermac.org

Address: Department of Cancer Research

Peter MacCallum Cancer Centre

305 Grattan Street

Melbourne VIC 3000

Australia

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: [10.1111/ans.14758](https://doi.org/10.1111/ans.14758)

Phone: +61422013953

Word Count: Main Text – 939 words
No Tables or Figures

Author Manuscript

Manuscript

When cancer immunotherapy is featured on the front pages of Time Magazine (1), the Australian Financial Review (2) and The Economist (3), there is a common realisation of the importance and significant impact that immunotherapy is having on advancing cancer therapy. Not since the discovery of chemotherapy in the late 1940s has there been such a rapid and substantive impact on cancer outcomes.

So what does the future hold for cancer surgery with the dawn of the immunotherapy?

Immunotherapy describes the utilisation/reactivation of the host immune system to eradicate cancer cells. A struggle between cancer cells and the immune system rages within a cancer patient, which can be summarised by three E's: *Elimination*, *Equilibrium* and *Escape* (4). The majority of malignant cells will be *eliminated* before they take root, however some generate a sanctuary whereby equilibrium between tumour growth and immune destruction is reached. Those that eventually *escape* immune control progress to locally advanced and metastatic disease.

The founding father of immunotherapy was William Coley, an orthopaedic surgeon, who in 1891 injected a mixture of dead bacteria into a patient to elicit an immune-mediated regression of sarcoma. However, limited capacity at the time to adequately understand the biology of the tumour microenvironment, coupled with the advent of more effective

treatment modalities such as radiation and cytotoxic chemotherapies, immunotherapy took a back seat until the 1970s. The renaissance of immunotherapy began with the discovery of the T-cell growth factor, Interleukin-2 (IL-2), in 1976. IL-2 was used to boost anti-tumour lymphocyte activity against melanoma and renal cell carcinoma (5), albeit with significant toxicity and thereby limited success. The problem wasn't that the T-cells needed further stimulation but rather was they were being inhibited from attacking cancer cells by immune checkpoint molecules; these include PD-1/PDL-1 and CTLA-4. Checkpoint inhibitor blockade disrupts these 'brakes' thus enhancing T-cell recognition and killing of cancer cells.

The impressive successes of checkpoint inhibitors: ipilimumab (Yervoy®), pembrolizumab (Keytruda®) and nivolumab (Opdivo®) in melanoma has expanded to multiple other tumour types including non-small cell lung cancer, microsatellite unstable colorectal cancer, gastric cancer, urothelial carcinoma, and metastatic head and neck squamous cell carcinoma. The first immune checkpoint inhibitor agent used clinically was ipilimumab, an anti-CTLA-4 antibody that enhances the activation of T-cells in lymphoid tissue for the treatment of unresectable or metastatic melanoma (6). Following this, pembrolizumab and nivolumab were employed, blocking the suppressive interaction between the PD-1 receptor (on T-cells) and its ligands PD-L1 (on cancer cells). The underlying premise of checkpoint inhibitor blockade is that they are most effective in immunogenic cancers (predominantly those with a high mutation burden), and hence currently are effective in less than 20% of cancers. Recent serendipitous observations of ongoing tumour control even after discontinuation of

immune checkpoint therapy has brought much excitement as the implication is enormous for patients with metastatic disease who have been through multiple lines of chemotherapy (7).

An emerging alternative is adoptive cellular therapy, where primary or metastatic tumours are surgically resected and tumour-specific lymphocytes are then extracted and expanded ex-vivo. These are then re-introduced to the patient after systemic lympho-depletion therapy. Currently, there are adoptive cellular therapy trials targeting melanoma, head and neck, renal and gynaecological malignancies. This has led to an additional indication for metatasectomy, which was once considered futile, but is now being used as a source to enrich tumour-specific lymphocytes for this novel therapy (8).

All this said it remains that the majority of cancers are not easily detected by the immune system and thus different strategies such as cancer vaccination against neo-antigens or differentially over-expressed self-antigens have become topical; successful examples include Sipuleucel-T (Provenge®) against castrate-resistant prostate cancer (9) and mutant *KRAS* peptide vaccine in pancreatic cancer (10). However, most cancer vaccines thus far have demonstrated minimal clinical benefit due to immune suppressive mechanisms; until the option of an immune checkpoint inhibitor blockade as companion therapy became evident. New combination cancer vaccine trials, such as the upcoming MYPHISMO trial (NCT03287427) targeting colorectal and adenoid cystic carcinomas and TG02 trial

(NCT02933944) aimed at mutant KRAS, will be crucial in advancing this mode of treatment (11).

As the primary recipient of most solid cancer referrals, surgeons have the unique opportunity to recognise and consider immunotherapy as an extension of their surgical armamentarium. With the push for personalised cancer care, tumour molecular and immune profiling is coming to the fore with the extension of immunotherapy as the fourth pillar in cancer treatment after surgery, chemotherapy and radiotherapy. Therefore, the potential scenarios for surgical-immunotherapy are genuinely exciting, as suggested below.

For early stage disease, the obvious choice is curative resection followed by adjuvant immunotherapy to reduce the risk of recurrence. In patients with locally advanced disease with threatened margin, neo-adjuvant immunotherapy can be utilised to downstage the disease and potentially allow for a R0 resection; with the option of adjuvant immunotherapy.

In cases of loco-regional disease, an immunotherapy 'sandwich' may be the best choice with immunotherapy given initially into an antigen-rich environment to aid in priming, followed by surgical debulking to enhance immunotherapy efficacy through disease burden reduction, and then backed-up with 'booster' immunotherapy.

Surgery still has a role in metastatic disease to debulk as well as harvest lymphocytes for adoptive cellular therapy, i.e. metastasectomy.

Whether utilised as primary or adjunctive therapy, immune-based therapies will undoubtedly improve surgical and oncological outcomes. Surgeons should embrace it as a new tool in the fight against cancer and facilitate further research in this field.

In conclusion, there is no definitive answer to our titular question, however surgical oncology is likely to remain a central pillar of cancer management, with immunotherapy becoming a fourth pillar for the management of cancer patients.

References

1. Park A. What If Your Immune System Could Be Taught to Kill Cancer? Time. 2016 April 4, 2016.
2. Gedye C. Tipping The Balance In The Fight Against Cancer. Australian Financial Review. 2017 December 27.
3. Unleash the T-cells: Enrolling the immune system in the fight against cancer. The Economist. 2017 September 16.
4. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. *Annu Rev Immunol*. 2004;22:329-60.
5. Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. *J Immunol*. 2014;192(12):5451-8.
6. Lipson EJ, Drake CG. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. *Clin Cancer Res*. 2011;17(22):6958-62.
7. McKay RR, Martini D, Moreira RB, Hamieh L, Norton C, Mullane SA, et al. Outcomes of PD-1/PD-L1 responders who discontinue therapy for immune-related adverse events (irAEs): Results of a cohort of patients (pts) with metastatic renal cell carcinoma (mRCC). *Journal of Clinical Oncology*. 2017;35(6_suppl):467-.
8. Crompton JG, Klemen N, Kammula US. Metastasectomy for Tumor-Infiltrating Lymphocytes: An Emerging Operative Indication in Surgical Oncology. *Ann Surg Oncol*. 2017.
9. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. *N Engl J Med*. 2010;363(5):411-22.
10. Weden S, Klemp M, Gladhaug IP, Moller M, Eriksen JA, Gaudernack G, et al. Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. *Int J Cancer*. 2011;128(5):1120-8.
11. MYPHISMO: MYB and PD-1 Immunotherapies Against Multiple Oncologies Trial. <https://ClinicalTrials.gov/show/NCT03287427>.

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Pham, TD;Narasimhan, V;Guerra, G;Kong, J;Desai, J;Ramsay, R;Heriot, A

Title:

Wither surgical oncology?

Date:

2019-01-01

Citation:

Pham, T. D., Narasimhan, V., Guerra, G., Kong, J., Desai, J., Ramsay, R. & Heriot, A. (2019). Wither surgical oncology?. ANZ JOURNAL OF SURGERY, 89 (1-2), pp.10-11. <https://doi.org/10.1111/ans.14758>.

Persistent Link:

<http://hdl.handle.net/11343/285222>